menu
    • menu

    Company profile for Crinetics Pharmaceuticals

    NEW Drugs in Dev: 7
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Crinetics was founded by scientists dedicated to creating new therapeutics for patients who suffer from endocrine disorders and endocrine-related cancers. Our scientific team has worked together for nearly two decades and has a depth of knowledge and expertise in discovering and developing small molecule drugs that selectively target G-protein coupled receptors (GPCRs).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Crinetics PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    6197 Cornerstone Court, Suite 111 San Diego, CA 92121
    Telephone
    Telephone
    1-858-450-6464
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://crinetics.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/crinetics-pharmaceuticals
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Crinetics Pharma Reveals January 2026 Inducement Grants
    Crinetics Pharma Reveals January 2026 Inducement Grants

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3217354/0/en/Crinetics-Pharmaceuticals-Announces-January-2026-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Crinetics Pharma Announces PALSONIFY & Atumelnant Update
    Crinetics Pharma Announces PALSONIFY & Atumelnant Update

    04 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/04/3212404/0/en/Crinetics-Pharmaceuticals-to-Provide-PALSONIFY-Business-Update-and-Announce-Topline-Results-from-Fourth-Cohort-of-Phase-2-Trial-of-Atumelnant-in-Congenital-Adrenal-Hyperplasia.html

    GLOBENEWSWIRE
    04 Jan 2026
    Share Share
    Crinetics Pharma Joins 44th J.P. Morgan Healthcare Conference
    Crinetics Pharma Joins 44th J.P. Morgan Healthcare Conference

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3208172/0/en/Crinetics-Pharmaceuticals-to-Participate-in-The-44th-Annual-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Crinetics Announces First Patient Dosed in Adrenal Hyperplasia
    Crinetics Announces First Patient Dosed in Adrenal Hyperplasia

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3204301/0/en/Crinetics-Announces-First-Patient-Dosed-in-Pivotal-Adult-Trial-of-Atumelnant-in-Congenital-Adrenal-Hyperplasia-CAH.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Crinetics Pharma Reveals Dec 2025 Inducement Grants Per Nasdaq
    Crinetics Pharma Reveals Dec 2025 Inducement Grants Per Nasdaq

    10 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/10/3203529/0/en/Crinetics-Pharmaceuticals-Announces-December-2025-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    10 Dec 2025
    Share Share
    Crinetics Initiates Phase 1/2 Trial For CRN09682
    Crinetics Initiates Phase 1/2 Trial For CRN09682

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3198798/0/en/Crinetics-Announces-First-Patient-Dosed-in-Phase-1-2-Trial-Evaluating-CRN09682-for-the-Treatment-of-Neuroendocrine-Tumors-and-Other-Somatostatin-Receptor-2-Expressing-Tumors.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search